Dr. Finian Tan, Deputy Chairman, Acting Chairman
Dr. Finian Tan founded Vickers Venture Partners of Singapore in 2005 with five other co-founders and is the Company Chairman.
Before starting Vickers, Finian was a Managing Director and Founding Partner at Draper Fisher Jurvetson (DFJ) ePlanet Asia Ventures. During his time at DFJ he led the investment into Baidu and remained its largest backer until the IPO.
Prior to DFJ ePlanet, Finian was Deputy Secretary of Trade and Industry for the Singapore Government where he oversaw the creation of the billion-dollar TIF fund and was subsequently appointed as Chairman of the fund.
As part of his earlier career path, Finian ran J.Aron (Singapore), the trading arm of Goldman Sachs.
Finian received his Doctor of Philosophy and Master of Philosophy in Engineering from Cambridge University. He received his B.Sc. in Engineering from the University of Glasgow, where he won every prize available to be won in all examinations in his years there.
Professor Thomas Rademacher, Co-founder, Executive Director & CEO
Professor Rademacher, MD, PhD, co-founded Gylden and has served as CEO since the Company’s formation.
He is an Emeritus Professor of Molecular Medicine at University College London (UCL) and a serial entrepreneur. Professor Rademacher is considered one of the founders of biotech in the early 1980s (recombinant proteins, monoclonal antibodies, glycobiology) and as an academic scientist has over 200 publications and 50 patents in his name. He was co-Founder of the field of Glycobiology and subsequent Glycobiology Institute in Oxford. He co-founded Oxford GlycoSciences, the first of Oxford University’s biotech spinouts, which, in 1998, was listed on the London Stock Exchange and reached a market capitalisation of £1.7 billion. After moving to UCL, Professor Rademacher founded several biotech spin-out companies, including Rodaris Pharmaceuticals Ltd.
In 2000, he entered into a collaboration with the Spanish Research Council and co-founded the first nanomedicine company, Midatech Ltd. Midatech floated on the AIM and NASDAQ stock exchanges in December 2015.
Professor Rademacher has authored over 200 publications and 50 patents – 19 of which are in the nanomedicine field. In addition to being a world leader in nanomedicine, he is also an expert in foetal-maternal medicine, having produced 25 publications and filed 5 patents related to preeclampsia.
Storme Moore-Thornicroft, Co-founder, Executive Director & COO
Storme Moore-Thornicroft co-founded Gylden and has served as COO since the Company’s formation.
Storme is responsible for business strategy formulation, implementation and execution at Gylden. In addition, she manages corporate and business development, company structure and organization, risk management, local and international partner relations and Board and shareholder relations.
She has operated in the biotechnology sector for over two decades and is particularly experienced in company formation and development. Storme has managed incorporation processes relating to the creation of corporate subsidiaries and other strategic structures such as Joint Ventures in Europe and in the US. She has managed financing processes for a number of early stage companies from corporate strategy and investor introduction through to investment agreement and completion. She also has experienced establishing strategic relationships with governments in South America, the Far East and areas of Africa.
Prior to Gylden, she co-founded Midatech Ltd, taking the role of Vice President, Corporate Management where she was responsible for corporate and business planning, implementation and execution of strategy and operations, resulting in technology development and commercialisation.
In her early career she served at University College London (UCL Business) as IP Manager where she was responsible for the prosecution and maintenance of IP portfolios generated for UCL spin-off companies.
Sergio Pagani, Executive Director & Group CFO
Sergio Pagani was previously Global Head of Commodities at ANZ Banking Group in Singapore and has more than 20 years of experience in international banking, finance and capital markets.
He has an extensive track record of delivering in a variety of senior positions in Zurich, London and Singapore, including at UBS Private Banking, Bankers Trust, Deutsche Bank, Dresdner Kleinwort Wasserstein, and Mitsubishi UFJ.
Sergio is also an active investor in biotech companies and serves as a Director on the Board of RWDC Industries, a Singapore-based company with leading technology in the field of biodegradable biopolymers.
Dr. Frank Tufaro, Non-Executive Director
Dr. Tufaro is COO of Replay Holdings, Inc. (San Diego) and brings a wealth of expertise and a proven track record in the biotechnology industry, particularly in the gene and oncolytic virus arena.
He founded and led several virus-based therapeutics and biopharmaceutical companies in the oncology space.
Dr. Tufaro started his career as Professor in the Department of Microbiology and Immunology at the University of British Columbia (1987-2003) and has authored numerous notable peer-reviewed scientific publications in the fields of virology and cancer. Currently he serves on executive and advisory boards of several biotech companies, with a commitment to advancing innovative solutions in biotechnology.
David Jackson, Non-Executive Director
David Jackson, formerly a Non-Executive Director at Phoenix Global Resources PLC and a Managing Director at Standard Chartered, brings over 40 years of diverse Board appointments in UK public and private sector companies as well as senior investment banking and asset management experience. He started his career as a Senior Legal Advisor at 3i Group PLC before moving into international investment banking in London and Asia.
Dr. Ricardo de Godoi M. Ferreira, Non-Executive Director
Dr. Ricardo de Godoi M. Ferreira, Non-Executive Director
Dr. Ricardo de Godoi M. Ferreira is the Director of Innovation at Bio-Manguinhos since 2024, formerly acting as the General Coordinator of Strategic Planning at the Oswaldo Cruz Foundation (Fiocruz) located in Rio de Janeiro, Brazil, a position he has held since 2018. He also serves as a Public Health Researcher there, since 2012.
Dr. Ricardo de Godoi M. Ferreira is highly experienced in the fields of genetic epidemiology and infectious diseases as well as bioinformatics. His experience in these areas extends to his positions on the Management Committee of the National Institute of Epidemiology of the Western Amazon, which he has held since 2017.
Dr. Poh Hui Chia, Non-Executive Director
Dr. Poh Hui Chia is Director of Vickers Venture Partners of Singapore and has been with the firm since 2018.
Poh Hui has been instrumental in establishing the Silicon Valley office of Vickers and has played a key role in sourcing and evaluating investment opportunities, particularly in the biotech and healthcare sectors. Her expertise in these areas, combined with her scientific background, enables her to identify promising opportunities and provide valuable insights to portfolio companies.
Poh Hui received her B.S. in Biochemistry from the University of Wisconsin-Madison and Ph.D. in Neuroscience from Stanford University. Her ground-breaking work on brain development and genetic diseases has garnered recognition in prestigious scientific journals, including Nature and Cell.
